Esperoct Approval History
Esperoct (turoctocog alfa pegol, N8-GP) is an extended half-life factor VIII molecule for the treatment of adults and children with hemophilia A.
Development History and FDA Approval Process for Esperoct
|Feb 19, 2019||FDA Approves Esperoct (turoctocog alfa pegol, N8-GP) for Hemophilia A|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.